BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302252% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Non-GAAP Adjusted Cost of Sales — Product by Year
Non-GAAP Adjusted Cost of Sales — Product ($M) ($M)
BeOne Medicines Non-GAAP Adjusted Cost of Sales — Product: $644M in FY2025, up 17.8% from a year earlier.
Latest, FY2025
644
Period ended Dec 31, 2025
Change on a year earlier
+17.8%
547 in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Adjusted cost of sales - products | $ | 137,403 | $ | 141,288 | $ | 643,974 | $ | 546,653”
Source: Form 8-K (filed 2026-02-26) ↗
Reported in Form 8-K EX-99.1 Non-GAAP Reconciliation Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP Adjusted Cost of Sales — Product ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 644 | +17.8% | Form 8-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 547 | +48.7% | Form 8-K (filed 2025-02-27) ↗ |
| FY2023 | Dec 31, 2023 | 368 | +29.8% | Form 8-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 283 | – | Form 8-K (filed 2024-02-26) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Non-GAAP Adjusted Cost of Sales — Product ($M), annual FY2022–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/adj-cogs-prod
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.